WO2008024398B1 - Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique - Google Patents

Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Info

Publication number
WO2008024398B1
WO2008024398B1 PCT/US2007/018571 US2007018571W WO2008024398B1 WO 2008024398 B1 WO2008024398 B1 WO 2008024398B1 US 2007018571 W US2007018571 W US 2007018571W WO 2008024398 B1 WO2008024398 B1 WO 2008024398B1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
chr
cycloalkyl
cycloalkenyl
ring
Prior art date
Application number
PCT/US2007/018571
Other languages
English (en)
Other versions
WO2008024398A2 (fr
WO2008024398A3 (fr
Inventor
Jean-Michel Vernier
La Rosa Martha Alicia De
Huanming Chen
Jim Zhen Wu
Gary Lee Larson
Ian Wayne Cheney
Original Assignee
Valeant Pharmaceuticals Int
Jean-Michel Vernier
La Rosa Martha Alicia De
Huanming Chen
Jim Zhen Wu
Gary Lee Larson
Ian Wayne Cheney
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2009002002A priority Critical patent/MX2009002002A/es
Priority to NZ575652A priority patent/NZ575652A/en
Application filed by Valeant Pharmaceuticals Int, Jean-Michel Vernier, La Rosa Martha Alicia De, Huanming Chen, Jim Zhen Wu, Gary Lee Larson, Ian Wayne Cheney filed Critical Valeant Pharmaceuticals Int
Priority to CA2661462A priority patent/CA2661462C/fr
Priority to ES07837199T priority patent/ES2420960T3/es
Priority to EP07837199.4A priority patent/EP2061465B1/fr
Priority to DK07837199.4T priority patent/DK2061465T3/da
Priority to AU2007288253A priority patent/AU2007288253B2/en
Priority to JP2009525618A priority patent/JP5419691B2/ja
Priority to BRPI0716715-6A priority patent/BRPI0716715B1/pt
Priority to PL07837199T priority patent/PL2061465T3/pl
Publication of WO2008024398A2 publication Critical patent/WO2008024398A2/fr
Publication of WO2008024398A3 publication Critical patent/WO2008024398A3/fr
Publication of WO2008024398B1 publication Critical patent/WO2008024398B1/fr
Priority to IL197161A priority patent/IL197161A/en
Priority to ZA2009/01977A priority patent/ZA200901977B/en
Priority to NO20091183A priority patent/NO343575B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/18—Aralkyl radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne un composé de formule IA: dans laquelle X = O ou S; Y est O ou S; q = 1 ou 0; et les autres substituants sont tels que definis dans la description. De tels composés peuvent affecter l'ouverture, ou moduler autrement, des canaux potassiques sensibles au voltage. Ils sont potentiellement utiles pour le traitement et la prévention de maladies et de troubles qui sont affectés par l'activation ou la modulation de canaux ioniques au potassium. Une telle condition est constituée par des troubles de crise.
PCT/US2007/018571 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique WO2008024398A2 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BRPI0716715-6A BRPI0716715B1 (pt) 2006-08-23 2007-08-22 Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potássio, seus usos, produto, composição, comprimido e cápsula
JP2009525618A JP5419691B2 (ja) 2006-08-23 2007-08-22 カリウムチャネルモジュレーターとしての４−（ｎ−アザシクロアルキル）アニリドの誘導体
CA2661462A CA2661462C (fr) 2006-08-23 2007-08-22 Derives de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
NZ575652A NZ575652A (en) 2006-08-23 2007-08-22 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators
EP07837199.4A EP2061465B1 (fr) 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
DK07837199.4T DK2061465T3 (da) 2006-08-23 2007-08-22 Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer
PL07837199T PL2061465T3 (pl) 2006-08-23 2007-08-22 Pochodne 4-(N-azacykloalkilo) anilidów jako modulatory kanałów potasowych
MX2009002002A MX2009002002A (es) 2006-08-23 2007-08-22 Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
ES07837199T ES2420960T3 (es) 2006-08-23 2007-08-22 Derivados de 4-(N-azacicloalquil)anilidas como moduladores de los canales de potasio
AU2007288253A AU2007288253B2 (en) 2006-08-23 2007-08-22 Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
IL197161A IL197161A (en) 2006-08-23 2009-02-22 Derivatives 4- (n-azacycloalkyl) anilides Preparations containing and using them
ZA2009/01977A ZA200901977B (en) 2006-08-23 2009-03-20 Derivatives of 4-(in-azacycloalkyl) anilides as potassium channel modulators
NO20091183A NO343575B1 (no) 2006-08-23 2009-03-20 Derivater av 4-(N-azacykloalkyl)-anilider, fremgangsmåte for fremstilling av slike forbindelser, preparater omfattende slike forbindelser samt anvendelse av slike forbindelser for forhindring eller behandling av sykdom

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83994106P 2006-08-23 2006-08-23
US60/839,941 2006-08-23

Publications (3)

Publication Number Publication Date
WO2008024398A2 WO2008024398A2 (fr) 2008-02-28
WO2008024398A3 WO2008024398A3 (fr) 2008-06-26
WO2008024398B1 true WO2008024398B1 (fr) 2008-08-14

Family

ID=39107384

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/018571 WO2008024398A2 (fr) 2006-08-23 2007-08-22 Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique

Country Status (23)

Country Link
US (1) US8293911B2 (fr)
EP (1) EP2061465B1 (fr)
JP (1) JP5419691B2 (fr)
KR (1) KR20090079191A (fr)
CN (1) CN101563085A (fr)
AR (1) AR062508A1 (fr)
AU (1) AU2007288253B2 (fr)
BR (1) BRPI0716715B1 (fr)
CA (1) CA2661462C (fr)
CL (1) CL2007002455A1 (fr)
DK (1) DK2061465T3 (fr)
ES (1) ES2420960T3 (fr)
IL (1) IL197161A (fr)
MX (1) MX2009002002A (fr)
NO (1) NO343575B1 (fr)
NZ (1) NZ575652A (fr)
PL (1) PL2061465T3 (fr)
PT (1) PT2061465E (fr)
RU (1) RU2009110172A (fr)
SG (1) SG174095A1 (fr)
TW (1) TW200827339A (fr)
WO (1) WO2008024398A2 (fr)
ZA (1) ZA200901977B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060097A1 (fr) 2011-10-25 2013-05-02 中国科学院上海药物研究所 Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
US7541357B2 (en) 2004-07-15 2009-06-02 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US7960436B2 (en) 2006-06-05 2011-06-14 Valeant Pharmaceuticals International Substituted arylamino-1,2,3,4-tetrahydro naphthalenes and-2,3-dihydro-1H-indenes as potassium channel modulators
US20080045534A1 (en) * 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
MX2009002002A (es) 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
US8993593B2 (en) * 2006-08-23 2015-03-31 Valeant Pharmaceuticals International N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.
US8367684B2 (en) 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010008894A1 (fr) * 2008-06-24 2010-01-21 Valeant Pharmaceuticals International Dérivés de benzyloxy anilide utiles en tant que modulateurs du canal potassique
TW201041857A (en) * 2009-05-11 2010-12-01 Lundbeck & Co As H Stable forms of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide
WO2010132487A1 (fr) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company Formes cristallines de (s)-7-([1,2,4]triazolo[1,5-a] pyridin -6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline et leurs utilisations
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
PE20120373A1 (es) 2009-05-12 2012-05-17 Albany Molecular Res Inc 7-([1,2,4]triazolo[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina
EP2590961A1 (fr) * 2010-07-08 2013-05-15 Pfizer Inc Amides pipéridinyl pyrimidine en tant qu'ouvreurs du canal potassique ko7
ES2625256T3 (es) 2011-10-14 2017-07-19 Bristol-Myers Squibb Company Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA
EP2899183B1 (fr) 2011-10-14 2018-09-19 Bristol-Myers Squibb Company Composés de tétrahydroisiquinoline substitués en tant qu'inhibiteurs du facteur Xia
JP6033318B2 (ja) 2011-10-14 2016-11-30 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物
CN108250128A (zh) * 2012-09-27 2018-07-06 江苏先声药业有限公司 作为钾通道调节剂的化合物
EP2978751B1 (fr) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tétrahydroisoquinolines comprenant des azoles substitués en tant qu'inhibiteurs du facteur xia
CN109641836A (zh) * 2016-06-10 2019-04-16 赛弗卢尔生命科学公司 氟化的2-氨基-4-(取代的氨基)苯基氨基甲酸酯衍生物
US10329516B2 (en) * 2016-12-20 2019-06-25 International Flavors & Fragrances Inc. Organoleptic compounds
CN111954663A (zh) * 2017-12-13 2020-11-17 赛弗卢尔生命科学公司 氟化的4-(取代的氨基)苯基氨基甲酸酯衍生物
RU2020126188A (ru) 2018-01-10 2022-02-10 Альинки Байофарма Соединения тетрагидроизохинолина
FI3790548T3 (fi) * 2018-05-11 2023-11-17 Xenon Pharmaceuticals Inc Menetelmiä jänniteriippuvaisen kaliumkanavan avaajan biosaatavuuden ja eksposition tehostamiseksi
CN110511220B (zh) * 2018-05-22 2022-04-01 上海挚盟医药科技有限公司 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用
JP2022508945A (ja) 2018-10-22 2022-01-19 カデント セラピューティクス，インコーポレーテッド カリウムチャネルモジュレーターの結晶形態
EP3917907A1 (fr) 2019-01-29 2021-12-08 Universitá Degli Studi Di Salerno Modulateurs de canaux ioniques potassiques et leurs utilisations
TW202128627A (zh) * 2019-10-10 2021-08-01 加拿大商再諾製藥公司 選擇性鉀通道調節劑之固態晶型
EP4054580A1 (fr) * 2019-11-08 2022-09-14 Xenon Pharmaceuticals Inc. Méthodes de traitement de troubles dépressifs
KR20220113411A (ko) 2019-12-06 2022-08-12 제논 파마슈티칼스 인크. KV7 칼륨 채널 개방제(opener)의 통증 치료를 위한 용도
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
CA3207191A1 (fr) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Ouvreur de canaux potassiques sensibles a la tension destine a etre utilise dans le traitement de l'anhedonie
WO2022173853A1 (fr) 2021-02-09 2022-08-18 Xenon Pharmaceuticals Inc. Thérapie conjointe pour le traitement de crises épileptiques
CN113698345B (zh) * 2021-10-27 2022-02-01 上海挚盟医药科技有限公司 作为钾通道调节剂的化合物及其制备和应用
EP4074696A4 (fr) * 2021-10-27 2024-01-31 Shanghai Zhimeng Biopharma Inc Composé en tant que régulateur de canal potassique, préparation et utilisation associées
TW202333693A (zh) * 2021-12-31 2023-09-01 大陸商上海翰森生物醫藥科技有限公司 苯并哌啶衍生物調節劑、其製備方法和應用
TW202404583A (zh) 2022-06-08 2024-02-01 加拿大商再諾製藥公司 吡啶胺衍生物及其作為鉀通道調節劑之用途
WO2024050389A1 (fr) * 2022-08-30 2024-03-07 Biohaven Therapeutics Ltd. Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda
WO2024067819A1 (fr) * 2022-09-30 2024-04-04 上海翰森生物医药科技有限公司 Modulateur de dérivé polycyclique contenant de la pipéridine, son procédé de préparation et son utilisation

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181803A (en) * 1973-12-14 1980-01-01 Eisai Co., Ltd. Propiophenone derivatives and preparation thereof
DE3337593A1 (de) 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
DE3369315D1 (en) * 1982-10-27 1987-02-26 Degussa Derivatives of 2-amino-3-acylamino-6-benzylamino pyridine with an anti-epileptic activity
DE3665538D1 (en) 1985-01-23 1989-10-19 Asta Pharma Ag Synergistic combination of flupirtin and non-steroidal anti-phlogistics
ATE43789T1 (de) * 1985-02-23 1989-06-15 Asta Pharma Ag Kombination von flupirtin und anticholinergisch wirkenden spasmolytika.
DE3604575A1 (de) 1985-02-23 1986-08-28 Degussa Ag, 6000 Frankfurt Kombination von flupirtin und anticholinergisch wirkenden spasmolytika
JP2583067B2 (ja) * 1987-08-04 1997-02-19 住友化学工業株式会社 モノアゾ化合物およびそれを用いて疎水性繊維材料を染色または捺染する方法
GB8800199D0 (en) * 1988-01-06 1988-02-10 Beecham Group Plc Pharmaceutical preparation
MC2029A1 (fr) 1988-05-16 1990-04-25 Asta Pharma Ag (n-heterocyclyl)-3 diamino-2,6 pyridines substituees et leurs n-oxydes,preparation de ces composes et leur application comme medicaments
US5629307A (en) * 1989-10-20 1997-05-13 Olney; John W. Use of ibogaine in reducing excitotoxic brain damage
US6004945A (en) * 1990-05-10 1999-12-21 Fukunaga; Atsuo F. Use of adenosine compounds to relieve pain
IN172468B (fr) * 1990-07-14 1993-08-14 Asta Medica Ag
US5643921A (en) * 1990-09-26 1997-07-01 E.R. Squibb & Sons, Inc. Cardiopulmonary bypass and organ transplant using a potassium channel activator
US5234947A (en) * 1991-11-07 1993-08-10 New York University Potassium channel activating compounds and methods of use thereof
DE4200259A1 (de) * 1992-01-08 1993-07-15 Asta Medica Ag Neue 1,2,4-triaminobenzol-derivate und verfahren zu deren herstellung
US5262419A (en) * 1992-06-11 1993-11-16 E. R. Squibb & Sons, Inc. Method for the prophylaxis and/or treatment of ulcerative gastrointestinal conditions using a potassium channel activator
CA2115792C (fr) * 1993-03-05 2005-11-01 David J. Mayer Methode de traitement de la douleur
US5428039A (en) * 1994-02-20 1995-06-27 The Center For Innovative Technology Method for electively achieving reversible hyperpolarized cardiac arrest
EP1634597A1 (fr) * 1994-09-22 2006-03-15 Richard Alan Smith Compositions comprenant du dextromethorphane et de la quinidine ou de la quinine pour le traitement de la labilité émotionnelle
US5679706A (en) * 1994-09-30 1997-10-21 Bristol-Myers Squibb Company Combination of a potassium channel activator and an antiarrhythmic agent
ATE300308T1 (de) * 1994-12-12 2005-08-15 Omeros Corp Bespüllungslösung und deren verwendung zur perioperativen hemmung von schmerzen, entzündungen und spasmen an einer wunde
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19701694A1 (de) * 1997-01-20 1998-07-23 Asta Medica Ag Neue Modifikationen des 2-Amino-4-(4-fluorbenzylamino)-l-ethoxycarbonyl-aminobenzen sowie Verfahren zu ihrer Herstellung
US5760007A (en) * 1997-07-16 1998-06-02 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating neuropathic pain
WO1999007411A1 (fr) * 1997-08-08 1999-02-18 Chugai Seiyaku Kabushiki Kaisha Remedes contre les complications du diabete
US6265417B1 (en) * 1997-12-18 2001-07-24 Abbott Laboratories Potassium channel openers
US6593335B1 (en) * 1997-12-18 2003-07-15 Abbott Laboratories Potassium channel openers
US6333337B1 (en) * 1998-01-27 2001-12-25 Icagen, Inc. Potassium channel inhibitors
US6211171B1 (en) * 1998-05-19 2001-04-03 Dalhousie University Use of antidepressants for local analgesia
JP3441970B2 (ja) 1998-06-30 2003-09-02 株式会社サミー 豆腐の製造方法及び製造装置
JP2000143510A (ja) 1998-11-16 2000-05-23 Taisho Pharmaceut Co Ltd 外用組成物
HUP0104676A3 (en) * 1998-12-14 2005-12-28 Cellegy Pharmaceuticals Inc So Compositions for the treatment of anorectal disorders and their use
US6281211B1 (en) * 1999-02-04 2001-08-28 Euro-Celtique S.A. Substituted semicarbazides and the use thereof
GB9903476D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Therapeutic agents
WO2000053225A1 (fr) * 1999-03-10 2000-09-14 Warner-Lambert Company Compositions analgesiques comprenant des composes anti-epileptiques, et leurs procedes d'utilisation
EP1163225A1 (fr) 1999-03-17 2001-12-19 Signal Pharmaceuticals, Inc. Composes et techniques de modulation des recepteurs des oestrogenes
AT409083B (de) 1999-04-01 2002-05-27 Sanochemia Pharmazeutika Ag Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
US6610324B2 (en) 1999-04-07 2003-08-26 The Mclean Hospital Corporation Flupirtine in the treatment of fibromyalgia and related conditions
GB9915414D0 (en) 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use
DK1200073T3 (da) 1999-07-06 2007-05-07 Lilly Co Eli Selektive iGluR5-receptorantagonister til behandling af migræne
US6472165B1 (en) * 1999-08-03 2002-10-29 Arzneimittelwerk Dresden Gmbh Modulatory binding site in potassium channels for screening and finding new active ingredients
DE60037321D1 (de) * 1999-08-04 2008-01-17 Icagen Inc Benzanilide als öffner des kaliumkanals
US6495550B2 (en) * 1999-08-04 2002-12-17 Icagen, Inc. Pyridine-substituted benzanilides as potassium ion channel openers
JP2003506388A (ja) * 1999-08-04 2003-02-18 アイカゲン インコーポレイテッド 疼痛および不安症を処置または予防するための方法
US6117900A (en) 1999-09-27 2000-09-12 Asta Medica Aktiengesellschaft Use of retigabine for the treatment of neuropathic pain
US6383511B1 (en) * 1999-10-25 2002-05-07 Epicept Corporation Local prevention or amelioration of pain from surgically closed wounds
US6538004B2 (en) * 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
US20020015730A1 (en) * 2000-03-09 2002-02-07 Torsten Hoffmann Pharmaceutical formulations and method for making
TWI287984B (en) * 2000-10-17 2007-10-11 Wyeth Corp Pharmaceutical composition for modulating bladder function
US6589986B2 (en) * 2000-12-20 2003-07-08 Wyeth Methods of treating anxiety disorders
US6469042B1 (en) * 2001-02-20 2002-10-22 Bristol-Myers Squibb Company Fluoro oxindole derivatives as modulators if KCNQ potassium channels
AU2002338333A1 (en) 2001-04-04 2002-10-21 Wyeth Methods for treating hyperactive gastric motility
US6831080B2 (en) * 2001-05-31 2004-12-14 Bristol-Myers Squibb Company Cinnamide derivatives as KCNQ potassium channel modulators
GB0121214D0 (en) * 2001-08-31 2001-10-24 Btg Int Ltd Synthetic method
WO2003068769A1 (fr) 2002-02-12 2003-08-21 Pfizer Inc. Composes non-peptidiques influant sur l'action de la gnrh
AUPS110302A0 (en) * 2002-03-14 2002-04-18 Biomolecular Research Institute Limited Novel chalcone derivatives and uses thereof
AU2003241453A1 (en) 2002-05-17 2003-12-02 Janssen Pharmaceutica N.V. Aminotetralin-derived urea modulators of vanilloid vr1 receptor
WO2003106454A1 (fr) * 2002-06-12 2003-12-24 Orchid Chemicals & Pharmaceuticals Ltd Derives de 1h-isoquinoline-oxazolidinone, et leur utilisation comme agents antibacteriens
AUPS312602A0 (en) * 2002-06-21 2002-07-18 James Cook University Organ arrest, protection, preservation and recovery
US7419981B2 (en) * 2002-08-15 2008-09-02 Pfizer Inc. Synergistic combinations of an alpha-2-delta ligand and a cGMP phosphodieterse 5 inhibitor
AU2003294441A1 (en) * 2002-11-22 2004-06-18 Bristol-Myers Squibb Company 1-aryl-2-hydroxyethyl amides as potassium channel openers
CA2505195C (fr) * 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones comme modulateurs de canaux potassiques
CA2511502A1 (fr) 2002-12-27 2004-07-15 H. Lundbeck A/S Derives de 1,2,4-triaminobenzene utiles pour traiter des troubles du systeme nerveux central
EP1606247A1 (fr) 2003-03-14 2005-12-21 H. Lundbeck A/S Derives d'aniline substitues
CA2519582A1 (fr) 2003-03-21 2004-09-30 H. Lundbeck A/S Derives de para-diaminobenzene substitues
EP1631546A1 (fr) 2003-04-25 2006-03-08 H. Lundbeck A/S Derives indole et indoline substitues
WO2004105795A1 (fr) 2003-05-27 2004-12-09 Altana Pharma Ag Combinaisons pharmaceutiques d'un inhibiteur de la pompe a protons et d'un compose modifiant la motilite gastro-intestinale
US20050070570A1 (en) 2003-06-18 2005-03-31 4Sc Ag Novel potassium channels modulators
WO2005025511A2 (fr) * 2003-09-10 2005-03-24 Cedars-Sinai Medical Center Administration assistee par les canaux potassiques d'agents a travers la barriere hemato-encephalique
JP4719151B2 (ja) * 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
US20050089559A1 (en) * 2003-10-23 2005-04-28 Istvan Szelenyi Combinations of potassium channel openers and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
DE10359335A1 (de) 2003-10-23 2005-05-25 Viatris Gmbh & Co. Kg Kombinationen aus Kaliumkanalöffnern und Natriumkanalinhibitoren oder Natriumkanal beeinflussenden Wirkstoffen zur Behandlung von Schmerzzuständen
ES2235626B1 (es) 2003-11-10 2006-11-01 Almirall Prodesfarma, S.A. Formas de administracion masticables, no comprimidas dosificadas individualmente.
TWI349666B (en) 2004-03-12 2011-10-01 Lundbeck & Co As H Substituted morpholine and thiomorpholine derivatives
WO2005100349A2 (fr) 2004-04-13 2005-10-27 Icagen, Inc. Pyridines polycycliques en tant que modulateurs de canal ionique du potassium
JP2007536229A (ja) * 2004-05-03 2007-12-13 デューク・ユニバーシティー 体重減少に作用するための組成物
UA89503C2 (uk) 2004-09-13 2010-02-10 Х. Луннбек А/С Заміщені похідні аніліну
JPWO2006054513A1 (ja) 2004-11-19 2008-05-29 キッセイ薬品工業株式会社 神経因性疼痛の予防又は治療剤
EP1688141A1 (fr) * 2005-01-31 2006-08-09 elbion AG Utilisation de flupirtine pour le traitement de la vessie hyperactive et des maladies associées et pour le traitement du syndrome du colon irritable
EP2298766B1 (fr) 2005-03-03 2013-09-18 H. Lundbeck A/S Formulations pharmaceutiques comprenant un dérivé de pyridine substitué
US7683058B2 (en) * 2005-09-09 2010-03-23 H. Lundbeck A/S Substituted pyrimidine derivatives
MX2009002002A (es) 2006-08-23 2009-07-22 Valeant Pharmaceuticals Int Derivados de 4-(n-azacicloalquil) anilidas como moduladores de canal de potasio.
MX2009005652A (es) 2006-11-28 2009-08-07 Valeant Pharmaceuticals Int Analogos 1,4 diamino biciclicos de retigabina como moduladores de canales de potasio.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013060097A1 (fr) 2011-10-25 2013-05-02 中国科学院上海药物研究所 Nouveau composé utilisé comme agoniste des canaux potassiques kcnq, son procédé de préparation et son utilisation

Also Published As

Publication number Publication date
ES2420960T3 (es) 2013-08-28
PT2061465E (pt) 2013-07-15
JP5419691B2 (ja) 2014-02-19
JP2010501568A (ja) 2010-01-21
WO2008024398A2 (fr) 2008-02-28
SG174095A1 (en) 2011-09-29
MX2009002002A (es) 2009-07-22
AR062508A1 (es) 2008-11-12
EP2061465A4 (fr) 2011-03-16
IL197161A (en) 2015-07-30
CA2661462A1 (fr) 2008-02-28
NO343575B1 (no) 2019-04-08
TW200827339A (en) 2008-07-01
PL2061465T3 (pl) 2014-03-31
ZA200901977B (en) 2010-02-24
EP2061465B1 (fr) 2013-04-10
US20080139610A1 (en) 2008-06-12
KR20090079191A (ko) 2009-07-21
BRPI0716715B1 (pt) 2021-07-06
RU2009110172A (ru) 2010-09-27
CN101563085A (zh) 2009-10-21
DK2061465T3 (da) 2013-07-08
CL2007002455A1 (es) 2008-04-18
AU2007288253A1 (en) 2008-02-28
AU2007288253B2 (en) 2013-05-02
IL197161A0 (en) 2009-12-24
BRPI0716715A2 (pt) 2013-09-03
NZ575652A (en) 2011-08-26
NO20091183L (no) 2009-05-08
WO2008024398A3 (fr) 2008-06-26
CA2661462C (fr) 2015-09-29
EP2061465A2 (fr) 2009-05-27
US8293911B2 (en) 2012-10-23

Similar Documents

Publication Publication Date Title
WO2008024398B1 (fr) Dérivés de 4-(n-azacycloalkyl) anilides en tant que modulateurs du canal potassique
RU2442778C2 (ru) Новые соединения, действующие как ингибиторы erk
WO2004005293A3 (fr) Composes diazaspirocycliques n-aryle et procedes de preparation et d'utilisation de ces derniers
WO2005028445A3 (fr) Urees heteroaromatiques modulant la fonction du recepteur vanilloiode-1 (vr1)
CA2565660A1 (fr) Composes aryl- ou heteroarylamides ortho-substitues
HUP0200804A2 (hu) 4-H-1-benzopirán-4-on-származékokat tartalmazó gyógyászati készítmények alkalmazása simaizomsejt proliferáció gátlására
WO2005105732A8 (fr) Composes methylaryl- ou heteroarylamides substitues
NO20003399D0 (no) <Alfa>-amionoamidderivater som er nyttige som smertestillende midler
TW200726760A (en) Chemical compounds IV
EP2743268A3 (fr) Composés cycliques condensés comme modulateurs du recepteur GPR40
HK1084026A1 (en) Compounds for the treatment of metabolic disorders
WO2006136837A3 (fr) Composes pharmaceutiques
CL2013001558A1 (es) El uso de compuestos moduladores o agonistas de los receptores de s1p para disminuir la frecuencia cardiaca en aproximadamente 2 latidos/minuto; metodo para aminorar, prevenir o limitar un efecto cronotropico negativo; un kit farmaceutico.
EP1798226A4 (fr) Derive de traizol
SG170739A1 (en) Iap bir domain binding compounds
MY152176A (en) Amino phosphate derivative and s1p receptor modulator having same as an active ingredient
WO2004073611A3 (fr) Composés pour le traitement de troubles métaboliques
BRPI0413540A (pt) moduladores gabanérgicos
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
RU2010107169A (ru) Фармацевтическая композиция, содержащая оптически активное соединение, обладающее активностью агониста рецептора тромбопоэтина, и промежуточное соединение для этого
MX2014004144A (es) Derivados de etinilo como moduladores alostericos del receptor de glutamato metabotropico del subtipo 5 (mglur5).
WO2004098496A3 (fr) Composes destines au traitement de troubles metaboliques
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
WO2004093806A3 (fr) Composes pour le traitement de troubles metaboliques
EP1868595A4 (fr) Composes pour le traitement de troubles metaboliques

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780039265.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837199

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2661462

Country of ref document: CA

Ref document number: 2009525618

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 197161

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/002002

Country of ref document: MX

Ref document number: 12009500357

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007288253

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 575652

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1085/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2009110172

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: A20090426

Country of ref document: BY

Ref document number: 2007837199

Country of ref document: EP

Ref document number: 1020097005943

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2007288253

Country of ref document: AU

Date of ref document: 20070822

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0716715

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090225